BioNexus Gene Lab Corp (BGLC)
About BioNexus Gene Lab Corp
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $7.4M
- Net income
- -$3.0M
- Total assets
- $9.3M
- Market cap
- $5.3M
- Gross margin
- 14.6%
- Operating margin
- -39.9%
- Net margin
- -40.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $7.4M
- Cost of revenue
- $6.3M
- Gross profit
- $1.1M
- Operating expenses
- $4.5M
- Operating income
- -$3.0M
- Income tax
- $0
- Net income
- -$3.0M
Balance sheet
- Total assets
- $9.3M
- Current assets
- $5.4M
- Total liabilities
- $637.9K
- Current liabilities
- $521.0K
- Shareholders’ equity
- $8.6M
Cash flow
- Operating cash flow
- -$1.8M
- Investing cash flow
- $944.8K
- Financing cash flow
- $298.8K
- Net cash flow
- -$400.6K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $5.3M
- Shares outstanding
- 3.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 11, 2020
BioNexus Gene Lab Corp (BGLC) Stock Price
- Reported a net loss of $3.0M in FY2025.
- Revenue declined 24% from FY2023 to FY2025.
- Gross margin of 14.6%, net margin -40.2%.
- Trading 86% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BioNexus Gene Lab Corp.
Write a review
News about BioNexus Gene Lab Corp
News & sentiment via Polygon.io
BioNexus Gene Lab Corp: frequently asked questions
Is BioNexus Gene Lab Corp an American company?
BioNexus Gene Lab Corp is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is BioNexus Gene Lab Corp publicly traded?
Yes — BioNexus Gene Lab Corp is a publicly traded company. Its stock trades under the ticker symbol BGLC on the NASDAQ.
What does BioNexus Gene Lab Corp do?
BioNexus Gene Lab Corp is an American Medical Devices company in the Health & Beauty sector.
